Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes
This is an interventional, multicenter, open label, phase II study designed to evaluate the safety and efficacy of Clofarabine in combination with low dose Cytarabine in untreated patients with poor risk of Myelodisplastic Syndromes.
Myelodysplastic Syndromes
DRUG: Clofarabine plus low dose Ara-C
To assess the remission rate according to the combination regimen, 19 months
Duration of response and survival, 19 months|Time to transformation in AML, 19 months|To determine the relationship of cytogenetic abnormalities and response to treatment, 19 months|To determine the safety and tolerability of the combination regimen, 19 months
This is an interventional, multicenter, open label, phase II study designed to evaluate the safety and efficacy of Clofarabine in combination with low dose Cytarabine in untreated patients with poor risk of Myelodisplastic Syndromes.